ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.

APM Aptorum Group Ltd

3.85
-0.98 (-20.29%)
After Hours
Last Updated: 18:10:15
Delayed by 15 minutes

Period:

Draw Mode:

Volume 34,428
Bid Price 3.70
Ask Price 4.10
News -
Day High 4.85

Low
1.35

52 Week Range

High
17.49

Day Low 3.70
Company Name Stock Ticker Symbol Market Type
Aptorum Group Ltd APM NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.98 -20.29% 3.85 18:10:15
Open Price Low Price High Price Close Price Prev Close
4.76 3.70 4.85 3.85 4.83
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
660 34,428 $ 4.12 $ 141,944 - 1.35 - 17.49
Last Trade Time Type Quantity Stock Price Currency
17:58:01 7 $ 3.83 USD

Aptorum Group Ltd Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
15.48M 4.17M - 431k -2.83M -0.68 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Aptorum News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No APM Message Board. Create One! See More Posts on APM Message Board See More Message Board Posts

Historical APM Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week5.005.133.704.7615,027-1.15-23.00%
1 Month5.655.88753.705.1222,062-1.80-31.86%
3 Months1.7117.491.408.442,564,8822.14125.15%
6 Months1.5917.491.358.421,223,8812.26142.14%
1 Year3.6517.491.358.02648,4680.205.48%
3 Years23.7035.401.3514.96578,689-19.85-83.76%
5 Years240.00332.801.3521.42482,756-236.15-98.40%

Aptorum Description

Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. Its lead projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.

Your Recent History

Delayed Upgrade Clock